Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors

Published:2019-11-05 Issue:22 Volume:62 Page:10272-10293
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Engelhardt Harald¹^ORCID,Böse Dietrich¹,Petronczki Mark¹,Scharn Dirk¹,Bader Gerd¹,Baum Anke¹,Bergner Andreas¹,Chong Eugene²^ORCID,Döbel Sandra¹,Egger Georg¹,Engelhardt Christian¹,Ettmayer Peter¹^ORCID,Fuchs Julian E.¹,Gerstberger Thomas¹,Gonnella Nina²^ORCID,Grimm Andreas¹,Grondal Elisabeth¹,Haddad Nizar²,Hopfgartner Barbara¹,Kousek Roland¹,Krawiec Mariusz²,Kriz Monika¹,Lamarre Lyne¹,Leung Joyce²,Mayer Moriz¹,Patel Nitinchandra D.²^ORCID,Simov Biljana Peric¹,Reeves Jonathan T.²^ORCID,Schnitzer Renate¹,Schrenk Andreas¹,Sharps Bernadette¹,Solca Flavio¹,Stadtmüller Heinz¹,Tan Zhulin²,Wunberg Tobias¹,Zoephel Andreas¹,McConnell Darryl B.¹

Affiliation:

1. Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria

2. Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States

Funder

?sterreichische Forschungsf?rderungsgesellschaft

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01169

Reference64 articles.

1. Roskoski, R. J. There are 49 FDA-Approved Small Molecule Protein Kinase Inhibitors as of 12 April 2019. http://www.brimr.org/PKI/PKIs.htm (accessed May 3, 2019).

2. Measuring and interpreting the selectivity of protein kinase inhibitors

3. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

4. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

5. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors;European Journal of Medicinal Chemistry;2024-12

2. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-11

3. Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity;Bioorganic & Medicinal Chemistry;2024-09

4. Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation;European Journal of Medicinal Chemistry;2024-09

5. The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery;Journal of Medicinal Chemistry;2024-08-22